Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 7/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676483 | 0.87 | MAPT (0.69) | MAPTGAAEDNRBEDNRATDP1 | |
| SCHEMBL12676480 | 0.84 | GAA (0.51) | MAPTGAAEDNRBEDNRAHPGD | |
| SCHEMBL12676318 | 0.84 | MAPT (0.51) | MAPTGAATDP1MAOBTP53 | |
| SCHEMBL12676477 | 0.82 | MAPT (0.60) | MAPTGAATDP1MAOBTP53 | |
| SCHEMBL29496818 | 0.82 | MAPT (0.60) | MAPTGAATDP1MAOBTP53 | |
| SCHEMBL12676320 | 0.78 | GAA (0.45) | MAPTGAAPTPN5 | |
| SCHEMBL17521179 | 0.78 | MAPT (0.42) | MAPTGAASLC5A2TDP1TP53 | |
| SCHEMBL12676274 | 0.78 | MAPT (0.51) | MAPTGAATDP1MAOBTP53 | |
| SCHEMBL13454123 | 0.78 | MAPT (0.56) | MAPTGAATDP1SMN1; SMN2MAOB | |
| SCHEMBL9189561 | 0.78 | GAA (0.47) | MAPTGAASLC5A2TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593069-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593069-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2016-02-11 | — | — | US | disclosed |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2016-02-11 | — | — | US | disclosed |
| US-9162968-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162968-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2014-12-18 | — | — | US | disclosed |
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2014-12-18 | — | — | US | disclosed |
| US-8722939-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722939-B2 | Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | CAMBRIA PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2011059821-A2 | CYCLOHEXANE-1,3-DIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371313-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885SLC5A2 3957/4885 |
| US-20160039740-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885SLC5A2 3957/4885 |
| US-20120264765-A1 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, HTT, CPT1B | MAPT 259/4885GAA 48/4885SLC5A2 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.